Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 230

1.

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.

White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lopes RD, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Sritara P, Tricoci P, Zeiher AM, Schwartz GG.

Eur Heart J. 2019 May 23. pii: ehz299. doi: 10.1093/eurheartj/ehz299. [Epub ahead of print]

PMID:
31121022
2.

Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.

Steg PG, Szarek M, Bhatt DL, Bittner VA, Brégeault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Committees and Investigators.

Circulation. 2019 May 23. doi: 10.1161/CIRCULATIONAHA.118.038840. [Epub ahead of print]

PMID:
31117810
3.

Alirocumab after Acute Coronary Syndrome. Reply.

Schwartz GG, Steg PG, Szarek M.

N Engl J Med. 2019 May 23;380(21):2077. doi: 10.1056/NEJMc1902955. No abstract available.

PMID:
31116934
4.

Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial.

Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Karpov Y, Moryusef A, Pordy R, Prieto JC, Roe MT, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators.

J Am Coll Cardiol. 2019 Mar 12. pii: S0735-1097(19)33921-X. doi: 10.1016/j.jacc.2019.03.013. [Epub ahead of print]

5.

Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.

Mani P, Puri R, Schwartz GG, Nissen SE, Shao M, Kastelein JJP, Menon V, Lincoff AM, Nicholls SJ.

JAMA Cardiol. 2019 Mar 6. doi: 10.1001/jamacardio.2019.0179. [Epub ahead of print]

PMID:
30840024
6.

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.

Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Kimura T, Kiss RG, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Tricoci P, Xavier D, Zeiher AM, Steg PG; ODYSSEY OUTCOMES Committees and Investigators.

J Am Coll Cardiol. 2019 Feb 5;73(4):387-396. doi: 10.1016/j.jacc.2018.10.039. Epub 2018 Nov 11.

7.

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators.

N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.

PMID:
30403574
8.

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.

Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S.

Lancet. 2018 Oct 13;392(10155):1311-1320. doi: 10.1016/S0140-6736(18)31652-0. Epub 2018 Oct 4.

PMID:
30293769
9.

Preoperative Use of Statins in Carotid Artery Stenting: A Systematic Review and Meta-analysis.

Texakalidis P, Giannopoulos S, Jonnalagadda AK, Chitale RV, Jabbour P, Armstrong EJ, Schwartz GG, Kokkinidis DG.

J Endovasc Ther. 2018 Oct;25(5):624-631. doi: 10.1177/1526602818794030. Epub 2018 Aug 13.

PMID:
30101624
10.

Ovarian Cancer Incidence in the U.S. and Toxic Emissions from Pulp and Paper Plants: A Geospatial Analysis.

Hanchette C, Zhang CH, Schwartz GG.

Int J Environ Res Public Health. 2018 Jul 31;15(8). pii: E1619. doi: 10.3390/ijerph15081619.

11.

Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial.

Nicholls SJ, Andrews J, Kastelein JJP, Merkely B, Nissen SE, Ray KK, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Griffith L, Kim SW, Janssan A, Di Giovanni G, Pisaniello AD, Scherer DJ, Psaltis PJ, Butters J.

JAMA Cardiol. 2018 Sep 1;3(9):815-822. doi: 10.1001/jamacardio.2018.2121.

PMID:
30046828
12.

Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone.

Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz ES, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN; IRIS Investigators.

Circulation. 2018 Sep 18;138(12):1210-1220. doi: 10.1161/CIRCULATIONAHA.118.034763.

PMID:
29934374
13.

Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.

Schrieks IC, Nozza A, Stähli BE, Buse JB, Henry RR, Malmberg K, Neal B, Nicholls SJ, Rydén L, Mellbin L, Svensson A, Wedel H, Weichert A, Lincoff AM, Tardif JC, Grobbee DE, Schwartz GG.

Diabetes Care. 2018 Aug;41(8):1792-1800. doi: 10.2337/dc18-0158. Epub 2018 Jun 14.

14.

Radon and lung cancer: What does the public really know?

Vogeltanz-Holm N, Schwartz GG.

J Environ Radioact. 2018 Dec;192:26-31. doi: 10.1016/j.jenvrad.2018.05.017. Epub 2018 Jun 5. Review.

15.

Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.

Stähli BE, Nozza A, Schrieks IC, Buse JB, Malmberg K, Mellbin L, Neal B, Nicholls SJ, Rydén L, Svensson A, Wedel H, Weichert A, Lincoff AM, Grobbee DE, Tardif JC, Schwartz GG.

J Clin Endocrinol Metab. 2018 Jul 1;103(7):2522-2533. doi: 10.1210/jc.2017-02772.

16.

Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial.

Schwartz GG, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Nicholls SJ, Olsson AG, Shah PK, Tardif JC, Kittelson J.

JAMA Cardiol. 2018 Feb 1;3(2):164-168. doi: 10.1001/jamacardio.2017.3833.

17.

Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes.

Savonitto S, Morici N, Nozza A, Cosentino F, Perrone Filardi P, Murena E, Morocutti G, Ferri M, Cavallini C, Eijkemans MJ, Stähli BE, Schrieks IC, Toyama T, Lambers Heerspink HJ, Malmberg K, Schwartz GG, Lincoff AM, Ryden L, Tardif JC, Grobbee DE.

Diab Vasc Dis Res. 2018 Jan;15(1):14-23. doi: 10.1177/1479164117735493. Epub 2017 Oct 20.

PMID:
29052439
18.

Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease.

Nicholls SJ, Ray KK, Johansson JO, Gordon A, Sweeney M, Halliday C, Kulikowski E, Wong N, Kim SW, Schwartz GG.

Am J Cardiovasc Drugs. 2018 Apr;18(2):109-115. doi: 10.1007/s40256-017-0250-3.

PMID:
29027131
19.

Enuresis and Constipation in a 12-Year-Old.

Schwartz GG, Hillman PR, Omoruyi EV, Mazur LJ.

Clin Pediatr (Phila). 2018 Jan;57(1):121-124. doi: 10.1177/0009922816688738. Epub 2017 Feb 13. No abstract available.

PMID:
28952347
20.

County level incidence rates of chronic lymphocytic leukemia are associated with residential radon levels.

Oancea SC, Rundquist BC, Simon I, Swartz S, Zheng Y, Zhou X, Sens MA, Schwartz GG.

Future Oncol. 2017 Sep;13(21):1873-1881. doi: 10.2217/fon-2017-0165. Epub 2017 Aug 24.

21.

Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.

Povsic TJ, Scott R, Mahaffey KW, Blaustein R, Edelberg JM, Lefkowitz MP, Solomon SD, Fox JC, Healy KE, Khakoo AY, Losordo DW, Malik FI, Monia BP, Montgomery RL, Riesmeyer J, Schwartz GG, Zelenkofske SL, Wu JC, Wasserman SM, Roe MT.

Cardiovasc Drugs Ther. 2017 Aug;31(4):445-458. doi: 10.1007/s10557-017-6739-9. Review.

PMID:
28735360
22.

Prediagnostic serum calcium and albumin and ovarian cancer: A nested case-control study in the Norwegian Janus Serum Bank Cohort.

Schwartz GG, Tretli S, Vos L, Robsahm TE.

Cancer Epidemiol. 2017 Aug;49:225-230. doi: 10.1016/j.canep.2017.07.004. Epub 2017 Jul 18.

23.

Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome.

Schwartz GG, Fayyad R, Szarek M, DeMicco D, Olsson AG.

Eur J Prev Cardiol. 2017 Aug;24(12):1294-1296. doi: 10.1177/2047487317708677. Epub 2017 May 15. Review.

PMID:
28504565
24.

Metformin prevents ischaemic ventricular fibrillation in metabolically normal pigs.

Lu L, Ye S, Scalzo RL, Reusch JEB, Greyson CR, Schwartz GG.

Diabetologia. 2017 Aug;60(8):1550-1558. doi: 10.1007/s00125-017-4287-2. Epub 2017 May 11.

25.

Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome.

Morici N, Savonitto S, Ponticelli C, Schrieks IC, Nozza A, Cosentino F, Stähli BE, Perrone Filardi P, Schwartz GG, Mellbin L, Lincoff AM, Tardif JC, Grobbee DE.

Am J Med. 2017 Sep;130(9):1068-1075. doi: 10.1016/j.amjmed.2017.02.033. Epub 2017 Mar 24.

PMID:
28344139
26.

Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.

Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN; IRIS Trial Investigators.

Diabetes Care. 2017 Apr;40(4):e47-e48. doi: 10.2337/dci16-0048. No abstract available.

27.

Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.

Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, Furie KL, Gorman MJ, Conwit R, Abbott JD, Jacoby DL, Kolansky DM, Pfau SE, Ling FS, Kernan WN; IRIS Investigators.

Circulation. 2017 May 16;135(20):1882-1893. doi: 10.1161/CIRCULATIONAHA.116.024863. Epub 2017 Feb 28.

28.

Who Should Receive Ezetimibe?

Schwartz GG.

J Am Coll Cardiol. 2017 Feb 28;69(8):922-923. doi: 10.1016/j.jacc.2016.12.013. No abstract available.

29.

Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.

Andrews J, Janssan A, Nguyen T, Pisaniello AD, Scherer DJ, Kastelein JJ, Merkely B, Nissen SE, Ray K, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Butters J, Girardi J, Miller R, Nicholls SJ.

Cardiovasc Diagn Ther. 2017 Feb;7(1):45-51. doi: 10.21037/cdt.2017.01.01.

30.

Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure.

Pitts R, Gunzburger E, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, Nicholls SJ, Shah PK, Tardif JC, Olsson AG, McMurray JJ, Kittelson J, Schwartz GG.

J Am Heart Assoc. 2017 Jan 10;6(1). pii: e004119. doi: 10.1161/JAHA.116.004119.

31.

Geographic distributions of motor neuron disease mortality and well water use in U.S. counties.

Schwartz GG, Rundquist BC, Simon IJ, Swartz SE.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):279-283. doi: 10.1080/21678421.2016.1264975. Epub 2016 Dec 25.

PMID:
28019106
32.

Association of Perioperative Statin Use With Mortality and Morbidity After Major Noncardiac Surgery.

London MJ, Schwartz GG, Hur K, Henderson WG.

JAMA Intern Med. 2017 Feb 1;177(2):231-242. doi: 10.1001/jamainternmed.2016.8005.

PMID:
27992624
33.

Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein.

Pitts R, Gunzburger E, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Nicholls SJ, Niesor EJ, Olsson AG, Shah PK, Tardif JC, Kittelson J, Schwartz GG.

J Am Coll Cardiol. 2016 Dec 6;68(22):2488-2490. doi: 10.1016/j.jacc.2016.09.932. No abstract available.

34.

Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.

Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN; IRIS Trial Investigators.

Diabetes Care. 2016 Oct;39(10):1684-92. doi: 10.2337/dc16-0798. Epub 2016 Jul 27.

35.

Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes.

Tardif JC, Rhainds D, Brodeur M, Feroz Zada Y, Fouodjio R, Provost S, Boulé M, Alem S, Grégoire JC, L'Allier PL, Ibrahim R, Guertin MC, Mongrain I, Olsson AG, Schwartz GG, Rhéaume E, Dubé MP.

Circ Cardiovasc Genet. 2016 Aug;9(4):340-8. doi: 10.1161/CIRCGENETICS.116.001405. Epub 2016 Jul 14.

36.

Motor neuron disease mortality rates in U.S. states are associated with well water use.

Schwartz GG, Klug MG.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Oct - Nov;17(7-8):528-534. Epub 2016 Jun 21.

37.

Serum calcium, albumin and tumor stage in cutaneous malignant melanoma.

Datta M, Savage P, Lovato J, Schwartz GG.

Future Oncol. 2016 Oct;12(19):2205-14. doi: 10.2217/fon-2016-0046. Epub 2016 Jun 16.

38.

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR; IRIS Trial Investigators.

N Engl J Med. 2016 Apr 7;374(14):1321-31. doi: 10.1056/NEJMoa1506930. Epub 2016 Feb 17.

39.

Adenylyl Cyclase 9 Polymorphisms Reveal Potential Link to HDL Function and Cardiovascular Events in Multiple Pathologies: Potential Implications in Sickle Cell Disease.

Niesor EJ, Benghozi R, Amouyel P, Ferdinand KC, Schwartz GG.

Cardiovasc Drugs Ther. 2015 Dec;29(6):563-572. doi: 10.1007/s10557-015-6626-1. Review.

PMID:
26619842
40.

Incidence rates of chronic lymphocytic leukemia in US states are associated with residential radon levels.

Schwartz GG, Klug MG.

Future Oncol. 2016 Jan;12(2):165-74. doi: 10.2217/fon.15.275. Epub 2015 Oct 30.

41.

Serum Calcium and Serum Albumin Are Biomarkers That Can Discriminate Malignant from Benign Pelvic Masses.

Kelly MG, Winkler SS, Lentz SS, Berliner SH, Swain MF, Skinner HG, Schwartz GG.

Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1593-8. doi: 10.1158/1055-9965.EPI-15-0443. Epub 2015 Jul 16.

42.

Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.

Erdmann E, Califf R, Gerstein HC, Malmberg K, Ruilope L, Schwartz GG, Wedel H, Volz D, Ditmarsch M, Svensson A, Bengus M.

Am Heart J. 2015 Jul;170(1):117-22. doi: 10.1016/j.ahj.2015.03.021. Epub 2015 Apr 2.

PMID:
26093872
43.

Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins.

Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, Mundl H, Olsson AG.

J Am Coll Cardiol. 2015 Jun 2;65(21):2267-75. doi: 10.1016/j.jacc.2015.03.544. Erratum in: J Am Coll Cardiol. 2015 Jul 21;66(3):334.

44.

Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein.

Niesor EJ, Schwartz GG, Perez A, Stauffer A, Durrwell A, Bucklar-Suchankova G, Benghozi R, Abt M, Kallend D.

Cardiovasc Drugs Ther. 2015 Feb;29(1):7-14. doi: 10.1007/s10557-015-6570-0.

PMID:
25749868
45.

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.

Tardif JC, Rhéaume E, Lemieux Perreault LP, Grégoire JC, Feroz Zada Y, Asselin G, Provost S, Barhdadi A, Rhainds D, L'Allier PL, Ibrahim R, Upmanyu R, Niesor EJ, Benghozi R, Suchankova G, Laghrissi-Thode F, Guertin MC, Olsson AG, Mongrain I, Schwartz GG, Dubé MP.

Circ Cardiovasc Genet. 2015 Apr;8(2):372-82. doi: 10.1161/CIRCGENETICS.114.000663. Epub 2015 Jan 11.

PMID:
25583994
46.

Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.

Viscoli CM, Brass LM, Carolei A, Conwit R, Ford GA, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Lovejoy AM, Parsons MW, Peduzzi PN, Ringleb PA, Schwartz GG, Spence JD, Tanne D, Young LH, Kernan WN; IRIS Trial investigators.

Am Heart J. 2014 Dec;168(6):823-9.e6. doi: 10.1016/j.ahj.2014.07.016. Epub 2014 Jul 28.

47.

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG.

Am Heart J. 2014 Nov;168(5):682-9. doi: 10.1016/j.ahj.2014.07.028. Epub 2014 Aug 7.

48.

Statins for acute coronary syndrome.

Vale N, Nordmann AJ, Schwartz GG, de Lemos J, Colivicchi F, den Hartog F, Ostadal P, Macin SM, Liem AH, Mills EJ, Bhatnagar N, Bucher HC, Briel M.

Cochrane Database Syst Rev. 2014 Sep 1;(9):CD006870. doi: 10.1002/14651858.CD006870.pub3. Review.

PMID:
25178118
49.

Evolving targets for lipid-modifying therapy.

Do RQ, Nicholls SJ, Schwartz GG.

EMBO Mol Med. 2014 Oct;6(10):1215-30. doi: 10.15252/emmm.201404000. Review.

50.

Vitamin D in blood and risk of prostate cancer: lessons from the Selenium and Vitamin E Cancer Prevention Trial and the Prostate Cancer Prevention Trial.

Schwartz GG.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1447-9. doi: 10.1158/1055-9965.EPI-14-0520. Review.

Supplemental Content

Loading ...
Support Center